MedTrace Logo

Viral Kinetics in HCV Clearance in Subjects With Hemophilia

NCT01704521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-04-06

Study results available
· View outcomes & findings →

Summary

This study will examine viral dynamic responses in subjects with chronic hepatitis C and hemophilia when treated with pegylated interferon + ribavirin and telaprevir.

Conditions

Interventions

DRUG

PegInterferon

DRUG

Ribavirin

DRUG

Telaprevir

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Vertex Pharmaceuticals Incorporated

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Kenneth Sherman

    lead OTHER

Principal Investigators

  • Kenneth E Sherman, MD, PhD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704521 on ClinicalTrials.gov